Taysha Gene Therapies gears up to approach regulators with a new candidate for a debilitating neurodegenerative disease

Nicole DeFeudis

Editor

After launching early last year, Taysha Gene Therapies quickly went about checking off key milestones. Within five months, it pulled in a hefty Series B …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Taysha Gene Therapies gears up to approach regulators with a new candidate for a debilitating neurodegenerative disease

Nicole DeFeudis

Editor

Sign up to read this article for free.

Lilly’s oral SERD makes strides in breast cancer with Phase 3 data

The Endpoints 100: The biotech industry braces for Trump 2.0

Exclusive: Bain-backed musculoskeletal biotech raises $120M for trio of clinical-stage biologics

Acelyrin says goodbye to the drug that got it a $540M IPO in 2023

Gene editing companies seek safer, less grueling conditioning methods for blood stem cell therapies

The key to faster, more impactful research? Put patients in the driver’s seat

Taysha Gene Ther­a­pies gears up to ap­proach reg­u­la­tors with a new can­di­date for a de­bil­i­tat­ing neu­rode­gen­er­a­tive dis­ease

Nicole DeFeudis

Editor

Sign up to read this article for free.

Lil­ly’s oral SERD makes strides in breast can­cer with Phase 3 da­ta

The End­points 100: The biotech in­dus­try braces for Trump 2.0

Ex­clu­sive: Bain-backed mus­cu­loskele­tal biotech rais­es $120M for trio of clin­i­cal-stage bi­o­log­ics

Ace­lyrin says good­bye to the drug that got it a $540M IPO in 2023

Gene edit­ing com­pa­nies seek safer, less gru­el­ing con­di­tion­ing meth­ods for blood stem cell ther­a­pies

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

Taysha Gene Therapies gears up to approach regulators with a new candidate for a debilitating neurodegenerative disease

Lilly’s oral SERD makes strides in breast cancer with Phase 3 data

The Endpoints 100: The biotech industry braces for Trump 2.0

Exclusive: Bain-backed musculoskeletal biotech raises $120M for trio of clinical-stage biologics

Acelyrin says goodbye to the drug that got it a $540M IPO in 2023

Gene editing companies seek safer, less grueling conditioning methods for blood stem cell therapies

The key to faster, more impactful research? Put patients in the driver’s seat